List of Excipients in Branded Drug NITYR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cycle Pharmaceuticals Ltd	NITYR	nitisinone	70709-002	GLYCERYL DIBEHENATE
Cycle Pharmaceuticals Ltd	NITYR	nitisinone	70709-002	LACTOSE MONOHYDRATE

NITYR Excipient Strategy and Commercial Opportunities in Nitisinone Drug Products

Last updated: August 8, 2026

NITYR is an oral nitisinone product for hereditary tyrosinemia type 1, a rare pediatric metabolic disorder. Its commercial position depends less on active-ingredient exclusivity than on pediatric usability, dose flexibility, palatability, formulation differentiation, and supply reliability. The strongest excipient opportunities are lactose-free tablets, orally disintegrating or dispersible dosage forms, pediatric liquids, and formulations that improve dose accuracy for weight-based treatment.

What is NITYR and how is it administered?

NITYR contains nitisinone, a fumarylacetoacetate hydrolase pathway inhibitor. FDA approved NITYR tablets on September 7, 2017, under NDA 209449 for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.[1]

The approved product is an immediate-release oral tablet available in 2 mg, 5 mg, and 10 mg strengths. The labeled initial dosage is 0.5 mg/kg administered twice daily, with subsequent adjustment based on biochemical and clinical response.[1]

Product attribute	NITYR position
Active ingredient	Nitisinone
Indication	Hereditary tyrosinemia type 1
FDA application	NDA 209449
Dosage form	Immediate-release tablet
Strengths	2 mg, 5 mg, 10 mg
Primary population	Pediatric and adult patients
Dosing basis	Weight-based, generally twice daily
Administration issue	Tablet swallowing and dose flexibility
Reference product context	Orfadin nitisinone products
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable

The weight-based dosing model creates a recurring need for small dose increments. That requirement favors products with multiple strengths, scored tablets, dispersible tablets, or liquid formulations.

What excipients are used in NITYR tablets?

NITYR uses conventional tablet excipients for immediate-release manufacture. The inactive-ingredient profile includes lactose monohydrate, microcrystalline cellulose, crospovidone, magnesium stearate, and film-coating components, according to the FDA labeling materials.[1]

The formulation strategy is technically conservative. It prioritizes manufacturability, rapid tablet disintegration, standard compression processes, and a familiar oral solid dosage form.

Excipient function	NITYR formulation role	Commercial relevance
Diluent	Supports tablet mass and content uniformity	Important because nitisinone dose is low
Binder or compression aid	Provides mechanical strength	Controls tablet robustness and friability
Superdisintegrant	Promotes rapid breakup after administration	Supports immediate release
Lubricant	Reduces sticking during compression	Can affect dissolution if overused
Film coating	Protects the tablet and improves handling	Can improve swallowability and product identification
Lactose	Tablet filler and processing aid	Creates a potential exclusion for lactose-intolerant patients

Because NITYR uses standard excipients, the commercial opportunity is unlikely to come from replacing one conventional filler with another without a patient or manufacturing benefit. The strongest case for reformulation would combine excipient changes with a distinct dosage form, improved stability, easier administration, or a validated clinical-use advantage.

What excipient strategies could improve NITYR?

Lactose-free reformulation

A lactose-free NITYR tablet could replace lactose monohydrate with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch-based excipients, or a co-processed filler system.

The commercial rationale is narrower than in general pediatric medicines because lactose intolerance is not the same as a milk-protein allergy. Even so, a lactose-free product could improve prescribing flexibility and simplify use in patients with dietary restrictions.

A reformulation would need to maintain:

• Nitisinone content uniformity at low drug loading.
• Immediate-release dissolution.
• Tablet hardness and friability.
• Long-term chemical stability.
• Compatibility with dietary management of tyrosinemia.
• Equivalent exposure or a clinically acceptable bridge to the existing product.

A lactose-free version would have limited standalone differentiation unless supported by a new dosage form, pediatric administration advantage, or market-access strategy.

Orally disintegrating tablets

An orally disintegrating tablet, or ODT, is one of the most credible product opportunities. Young children may have difficulty swallowing conventional tablets, and caregivers may need to administer treatment outside controlled clinical settings.

Potential excipient systems include:

• Mannitol-based ODT matrices.
• Crospovidone or croscarmellose sodium as superdisintegrants.
• Low-moisture direct-compression excipients.
• Taste-masking polymers.
• Flavors and sweeteners compatible with chronic pediatric use.

The central technical issue is taste. Nitisinone products require chronic administration, so an ODT with poor taste could reduce adherence even if disintegration performance is strong. The formulation must address both rapid oral disintegration and bitter-drug exposure in the mouth.

An ODT could support a new patent estate around composition, taste masking, disintegration time, stability, and pediatric administration. The claims would need to distinguish the product from conventional nitisinone tablets and earlier oral formulations.

Dispersible or water-dispersible tablets

A dispersible tablet could provide a lower-cost alternative to an ODT. The tablet would be dispersed in a defined volume of water before administration, allowing caregivers to administer a liquid-like dose without commercial dependence on a bottled suspension.

This format could support:

• Easier administration to infants and young children.
• Flexible dose measurement.
• Reduced swallowing burden.
• Lower packaging and shipping complexity than a ready-to-use liquid.
• Potential use in countries with limited cold-chain or pharmacy-compounding infrastructure.

The formulation must control sedimentation, redispersion, dose uniformity, and residual drug in the administration vessel. A label would need precise instructions on water volume, mixing, immediate use, and disposal of leftovers.

Oral liquid formulation

A ready-to-use nitisinone oral solution or suspension would address the largest administration gap in the current tablet presentation. The principal excipient challenges are chemical stability, solubility, taste, preservative selection, and dosing-device accuracy.

Potential formulation approaches include:

Approach	Benefits	Principal risks
Aqueous solution	Uniform dose and easy administration	Solubility and chemical degradation
Aqueous suspension	Lower solubilization burden	Sedimentation and dose variability
Concentrated solution	Smaller administration volume	Taste intensity and measurement error
Powder for reconstitution	Longer shelf life before use	Reconstitution variability
Lipid or cosolvent system	May improve solubility	Pediatric tolerability and regulatory burden

The most commercially practical liquid product would likely use a calibrated oral syringe and a concentration designed around common weight-based doses. A single concentration can simplify supply, but multiple concentrations may reduce administration volume across infants, children, and adults.

Taste-masked pediatric formulation

Taste masking could create a more defensible commercial product than a simple lactose-free tablet. Technologies may include polymer coating, ion-exchange resins, lipid barriers, cyclodextrins, or multiparticulate delivery.

A taste-masked formulation must avoid delaying nitisinone release after swallowing. It also must remain stable under the moisture and temperature conditions encountered in pediatric packaging.

Potential intellectual-property claims could cover:

• Nitisinone particles coated with a defined polymer layer.
• A specified dissolution profile at gastric pH.
• A defined bitterness-reduction threshold.
• Multiparticulate capsules or sachets.
• A taste-masked suspension with a specific particle-size distribution.
• A combination of nitisinone with a particular sweetener and masking agent.

What formulation patents could protect a NITYR follow-on product?

A defensible formulation patent would need more than a list of routine excipients. The strongest claims would link composition to a measurable performance result.

Patent subject	Potential claim focus	Strength
Lactose-free tablet	Defined excipient ratio and dissolution profile	Low to moderate unless unexpected results exist
ODT	Nitisinone, superdisintegrant, taste-masking system, and disintegration time	Moderate to strong
Oral suspension	Particle size, viscosity, sedimentation, and dose uniformity	Moderate
Ready-to-use solution	Solubilizer, pH range, preservative, and stability period	Moderate to strong if stability is unexpected
Multiparticulate product	Coated particles with immediate-release behavior	Stronger if technically distinctive
Administration kit	Product, syringe, cup, and dose-calculation system	Limited composition protection, possible device or method protection
Manufacturing process	Granulation, coating, drying, or containment process	Strong if difficult to design around

Method-of-use patents may cover administration to specified pediatric subgroups, dosing adjustments based on succinylacetone levels, or treatment protocols involving a particular formulation. Such claims may face eligibility, obviousness, and written-description challenges if they merely restate known nitisinone treatment practices.

When does NITYR lose exclusivity?

NITYR received orphan-drug designation for hereditary tyrosinemia type 1. Orphan exclusivity generally runs for seven years from approval and blocks FDA approval of another product for the same disease or condition unless the competing product is clinically superior.[2]

For NITYR, the seven-year orphan-exclusivity period began on September 7, 2017. The principal orphan-exclusivity period therefore ran to September 7, 2024, subject to the statutory framework and FDA records.

The product’s commercial protection is separate from patent protection. Orphan exclusivity does not prevent all competing development, and it does not necessarily prevent products with different indications, clinically superior products, or products that qualify under a different regulatory pathway.

Protection	NITYR timing or status
FDA approval	September 7, 2017
Seven-year orphan exclusivity	Generally through September 7, 2024
Small-molecule patent protection	Must be assessed through current Orange Book and patent records
Biosimilar exclusivity	Not applicable
Generic entry	Depends on listed patents, regulatory exclusivity, and ANDA litigation

What is the Orange Book status of NITYR?

NITYR is an NDA-approved small-molecule product and is therefore evaluated through the FDA Orange Book framework. Orange Book entries may include patent information, regulatory exclusivity, dosage-form data, and therapeutic-equivalence codes.[3]

The key diligence questions are:

1. Whether NDA 209449 has listed patents.
2. Whether those patents cover the active ingredient, formulation, method of use, or drug product.
3. Whether any listed patents have expired, been delisted, or remain relevant to an ANDA certification.
4. Whether the FDA has granted or removed any exclusivity codes.
5. Whether the proposed generic would need a Paragraph IV certification.

A Paragraph IV challenge would allege that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder receives notice, the filing of patent litigation within the statutory period can trigger a 30-month stay of FDA approval, subject to court and regulatory exceptions.[4]

For an improved excipient product, a 505(b)(2) applicant would face a different strategy from an ANDA applicant. A 505(b)(2) application may rely partly on existing findings for nitisinone while supporting a new dosage form, concentration, route-related feature, or formulation. The applicant would need to address any listed patents and exclusivity that FDA identifies as relevant.

Are biosimilar risks relevant to NITYR?

No. NITYR contains the small molecule nitisinone, not a biologic. The relevant competitive threats are:

• Generic nitisinone tablets.
• 505(b)(2) nitisinone liquids or pediatric formulations.
• Compounded oral suspensions.
• Alternative nitisinone products marketed in other jurisdictions.
• Future therapies for hereditary tyrosinemia type 1 that reduce reliance on nitisinone.

A biosimilar filing under the Public Health Service Act is not the expected pathway for a nitisinone competitor. The applicable routes are generally ANDA, 505(b)(2), or a full NDA, depending on the product’s differences from the reference product.

Which companies are challenging or competing with NITYR?

The principal commercial comparator is Orfadin, marketed by Swedish Orphan Biovitrum, or Sobi. Orfadin has been marketed in capsule and oral-suspension presentations in certain markets. NITYR was developed as a tablet-based nitisinone product and competes on dosage form, supply, price, and patient access.

Product	Company	Dosage-form relevance
NITYR	Cycle Pharmaceuticals	Immediate-release tablets
Orfadin	Sobi	Capsules and oral suspension in relevant markets
Compounded nitisinone	Pharmacies and institutions	Variable formulation and quality controls
Future generic nitisinone	Potential ANDA sponsors	Likely tablet-led competition
Future 505(b)(2) products	Specialty pharmaceutical companies	Potential liquid, ODT, or dispersible products

The most direct competitive gap is a commercially available, palatable, dose-flexible pediatric formulation with robust stability and a validated administration device.

How strong is the patent estate for an excipient-based NITYR product?

A conventional tablet reformulation would generally have a weaker patent position than a technically differentiated liquid, ODT, or multiparticulate product. Excipient patents are vulnerable when the selected ingredients and proportions are predictable from standard pharmaceutical practice.

Patent strength improves when the applicant can show:

• Unexpected nitisinone stability.
• A meaningful improvement in taste.
• Better pediatric adherence or administration accuracy.
• A dissolution profile that solves a known formulation problem.
• Reduced dose variability after dispersion or suspension.
• A manufacturing process that materially improves content uniformity.
• Stability across a broad temperature and humidity range.
• A formulation that avoids a known compatibility problem.

The most valuable portfolio would combine composition claims, process claims, drug-product claims, and method-of-use claims. Geographic filing should prioritize the United States, European Patent Convention states, Japan, China, Canada, Australia, and countries with established rare-disease reimbursement markets.

What licensing deals and commercial opportunities are available?

The commercial opportunity is strongest for companies with one of four capabilities:

1. Pediatric formulation development.
2. Rare-disease distribution and reimbursement access.
3. Specialty pharmacy and patient-support infrastructure.
4. Manufacturing of low-dose, high-content-uniformity solid or liquid dosage forms.

Potential deal structures include:

Deal structure	Strategic use
Formulation license	Transfer of an ODT, liquid, or taste-masked technology
Regional commercialization license	Local access and rare-disease distribution
Co-development agreement	Shared clinical, formulation, and regulatory costs
Contract manufacturing agreement	Supply of a differentiated dosage form
Device-plus-drug partnership	Oral syringe, dispersible tablet, or administration kit
Patent acquisition	Purchase of formulation or process rights

Revenue exposure is concentrated because hereditary tyrosinemia type 1 is rare. A differentiated product may command specialty pricing, but total volume is limited. Commercial value therefore depends on global registration, reimbursement, patient identification, and reliable long-term supply rather than mass-market prescription volume.

What generic launch scenarios exist for NITYR?

Scenario 1: Conventional tablet generic

A generic sponsor could target 2 mg, 5 mg, and 10 mg tablets through an ANDA, subject to reference-product requirements and patent certifications. Price erosion would be greatest if several sponsors launch simultaneously.

Scenario 2: First generic with limited competition

A single early filer may obtain commercial advantages under the ANDA framework if statutory conditions are satisfied. The launch could preserve significant pricing power during the period of limited competition.

Scenario 3: 505(b)(2) pediatric liquid

A liquid sponsor could avoid direct tablet competition by addressing an administration gap. This product could support premium pricing if it demonstrates better dose accuracy, palatability, stability, or caregiver usability.

Scenario 4: Compounded-product substitution

Compounding may compete with commercial liquids where no approved liquid is available. Approved products have advantages in quality controls, labeling, stability data, and payer acceptance.

Scenario 5: Product-line competition

NITYR could face competition from a company offering tablets, capsules, suspension, and administration devices as a coordinated portfolio. This approach could improve switching control across pediatric and adult populations.

Key Takeaways

• NITYR is a nitisinone tablet product approved for hereditary tyrosinemia type 1.
• Its orphan exclusivity began in September 2017 and generally ran through September 2024.
• Biosimilar competition is irrelevant because nitisinone is a small molecule.
• The strongest excipient opportunities are lactose-free tablets, ODTs, dispersible tablets, oral liquids, and taste-masked multiparticulates.
• A routine excipient substitution is unlikely to create strong exclusivity by itself.
• Patent value improves when excipient selection produces unexpected stability, taste, dissolution, dose-uniformity, or administration results.
• Generic tablet entry and 505(b)(2) pediatric formulations are the principal competitive scenarios.
• Commercial success depends on global rare-disease distribution, reimbursement, formulation usability, and supply reliability.

FAQs

Can NITYR be reformulated as an oral suspension?

Yes. A suspension could improve administration for young children, but development must establish sedimentation control, redispersibility, dose uniformity, taste, preservative performance, and stability.

Would a lactose-free NITYR tablet qualify for new patent protection?

Possibly, but a lactose-free composition alone may be vulnerable to obviousness objections. Stronger protection would require a defined composition linked to an unexpected technical or clinical result.

Is an NITYR oral liquid eligible for a 505(b)(2) application?

A new oral liquid may be suitable for the 505(b)(2) pathway if it relies partly on existing findings for nitisinone while requiring new formulation, stability, dosing, or clinical information.

What excipient issue is most important for pediatric nitisinone?

Palatability is likely the highest-value issue for a new pediatric formulation. Taste, dose accuracy, and ease of administration directly affect chronic treatment adherence.

Could an administration device create separate NITYR exclusivity?

A device may support separate patent or regulatory protection when it provides a distinct dosing function, improves accuracy, or is integrated with a new formulation. Device protection would not automatically protect the underlying nitisinone composition.

References

1. U.S. Food and Drug Administration. (2017). NITYR (nitisinone) tablets, prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209449s000lbl.pdf

2. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity. FDA. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments, patent certifications, and 30-month stays. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments-questions-and-answers-category-2-generic-drug-product-applications